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This review presents key publications from the
research field of sepsis published in Critical Care and
other relevant journals during 2013. The results of
these experimental studies and clinical trials are
discussed in the context of current scientific and
clinical background. The discussion highlights and
summarises articles on four main topics: sepsis
pathogenesis, diagnostic and prognostic biomarkers,
potential new therapies, and epidemiologic and
outcome studies.found between elevated levels of soluble RAGE and mor-Introduction
Despite intense experimental and clinical research activ-
ity over the past decades, sepsis still remains an elusive
syndrome. Actual understanding has led to international
recommendations on diagnosis and treatment [1], but
management of severe sepsis and septic shock in the
ICU still represents a major challenge for clinicians in
2014, with high mortality rates. The past year’s contribu-
tion to the field of sepsis research was quite prolific, and
the aim of this review is to summarise the relevant find-
ings of research articles that were published in 2013 in
Critical Care and other relevant journals. We focus on
advances in the understanding of sepsis physiopathology,
diagnostic and prognostic biomarkers, potential new
therapies, and epidemiologic and outcome studies.
Sepsis pathophysiology
In pulmonary infection by Staphylococcus aureus, host
defence mechanisms contribute to lung damage by re-
leasing damage-associated molecular patterns. High-
mobility group box 1 (HMGB1) is a damage-associated
molecular pattern of particular interest, acting as a cyto-
kine via the toll-like receptor 4 (TLR4) and the receptor
for advanced glycation end-products (RAGE). In a
mouse model of S. aureus pneumonia, histologic signs
of acute lung injury were reduced by adjunction of anti-* Correspondence: djillali.annane@rpc.aphp.fr
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1β [2]. Using TLR4 and RAGE knockout mice in the
same septic model, the authors showed that TLR4 defi-
ciency did not influence lung pathology but RAGE defi-
ciency led to attenuated lung damage. RAGE-deficient
mice had lower tumour necrosis factor alpha and IL-6
levels in bronchoalveolar fluid at 24 hours post-
infection, but not TLR4-deficient mice. This study sug-
gests distinct harmful roles of HMGB1 and RAGE, but
not of TLR4, in the development of lung injury during
the early phase of severe pneumonia caused by S. aureus.
These findings are in accordance with the association
tality and acute respiratory distress syndrome (ARDS) in
33 patients admitted to the ICU for community-acquired
pneumonia [3].
B- and T-lymphocyte attenuator (BTLA) is a co-
inhibitory receptor that is known to potently inhibit CD4+
T-cell and B-cell function [4]. Whether BTLA plays a role
in driving lymphocyte dysfunction and apoptosis is ques-
tioned. In 11 septic ICU patients, a significantly higher
percentage of circulating lymphocytes expressing BTLA
was found, compared with patients with nonseptic sys-
temic inflammatory response syndrome (SIRS) [5]. Fur-
thermore, a higher frequency of CD4+BTLA+ cells was
found in SIRS patients who subsequently developed in-
fection. In an experimental caecal ligation and puncture
mouse sepsis model, including BTLA−/− mice, it was
shown that BTLA contributed to the apoptosis of T cells
and B cells in the thymus and the spleen, and was associ-
ated with peripheral T-cell and B-cell reduction. BTLA
could be a potential therapeutic target/risk marker for
patients susceptible to developing subsequent secondary
infections.
Nuclear factor-κB is a key transcriptional regulator of in-
flammation and organ injury. In this respect, Devaney and
colleagues investigated the role of nuclear factor-κB inhib-
ition by intrapulmonary delivery of a viral vector encoding
the nuclear factor-κB inhibitor IκBα in a rat model of
Escherichia coli pneumonia [6]. In acute pneumonia (that
is, 4 hours after bacterial instillation), IκBα overexpression
enhanced animal survival, improved arterial oxygenation,BioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any
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significantly decreased alveolar IL-1β production. How-
ever, in a prolonged pneumonia model (that is, 72 hours
after bacterial instillation), IκBα overexpression increased
the lung E. coli bacterial load and the proportion of neu-
trophils in the alveolar infiltrate, and worsened E. coli-
induced histologic injury. Alveolar levels of IL-1β and
tumour necrosis factor alpha were also increased. This
study demonstrates the dual role of nuclear factor-κB in
infection, and stresses the detrimental effects of a strategy
to inhibit nuclear factor-κB if not temporally targeted.
The innate and adaptive immune systems are involved
in the pathogenesis of sepsis, and B cells are thought to
contribute to the immunosuppressive shift observed dur-
ing sepsis. Monserrat and colleagues demonstrated in 52
patients with septic shock a reduction of circulating B
lymphocytes and a relation between a low percentage of
activated regulatory cells and an increased 28-day mor-
tality [7]. Further studies are warranted to specify the
mechanisms by which these alterations contribute to the
evolution from sepsis to septic shock.
The signalling molecule nitric oxide may also play a
role in the pathophysiology of ARDS. Citrulline is a sub-
strate for nitric oxide synthase. It was hypothesised that
citrulline levels would decrease during sepsis, leading to
a fall in nitric oxide production in the lung and potenti-
ating the development of ARDS. Ware and colleagues
demonstrated that very low citrulline levels are associ-
ated with ARDS [8]. This association may be due to a
decrease in citrulline availability or citrulline overcon-
sumption for nitric oxide synthesis but also may result
from an arginine deficiency syndrome. In any case, the
results from this study reinforce the rationale for a study
of citrulline supplementation in critically ill patients.
Mitochondrial dysfunction has been implicated as a
causative mechanism for reduced activity of immune
cells in sepsis. Evolution of mitochondrial respiration
function in human peripheral blood immune cells was
assessed by Sjövall and colleagues within 48 hours of
sepsis onset, and at days 3 to 4 and days 6 to 7, as well
as its relation to outcome [9]. Peripheral blood immune
cells from 20 patients with severe sepsis or septic shock
were analysed with high-resolution respirometry and
compared with 31 controls. The results showed that cel-
lular respiration of peripheral blood immune cells pre-
sents an amplified capacity during the first week of
sepsis, because of an increase in both mitochondrial
content and oxidative phosphorylation capacity. Nonsur-
vivors displayed the same increase in respiration as the
survivors. These findings argue against mitochondrial
dysfunction in immune cells at sepsis onset.
Malondialdehyde (MDA), an end-product of lipid per-
oxidation, is one of the molecules involved in toxic ef-
fects of oxidative stress. Toufekoula and colleaguesdemonstrated that MDA levels measured in 93 patients
with ventilator-acquired pneumonia due to multidrug-
resistant bacteria were increased in cases of hepatic dys-
function or ARDS, but were lower in patients with acute
renal failure [10]. Results of this study are important be-
cause they confirm that oxidative stress is compartmen-
talised during sepsis. This compartmentalisation should
be borne in mind for designing future trials evaluating
antioxidant agents in sepsis.
Septic patients frequently suffer from compromised sen-
sitivity of the vasculature to pressor hormones, such as
angiotensin II [11]. Arap1 is a receptor-associated protein
of the angiotensin receptor 1 that enhances membrane
trafficking leading to improved sensitivity. In an endotox-
aemic mouse model, Arap1 was markedly downregulated
by sepsis, and sepsis-induced circulatory failure worsened
in Arap1-deficient mice [12]. Loss of Arap1 is thus a newly
identified mechanism for vascular hyporeactivity in septic
patients, and adds to the already identified factors: endo-
thelial injury, arginine–vasopressin system dysfunction, re-
lease of other vasodilatory inflammatory mediators, and
muscle hyperpolarisation [13].
Vassiliou and colleagues demonstrated that Aquaporin-
1, a water channel protein present in migratory cells, was
upregulated in mice polymorphonuclear granulocytes after
stimulation by lipopolysaccharide (LPS), was involved
in LPS-induced polymorphonuclear granulocyte plasma
membrane permeability, and may play a role in poly-
morphonuclear granulocyte migration to the site of infec-
tion [14]. Further studies are needed to clarify the
regulation of the aquaporin-1 signal transduction pathway
and its functional significance to better define its role in
sepsis physiopathology.
Diagnostic and prognostic markers in sepsis
Although the sepsis definition is based on internationally
accepted criteria [1], symptoms and signs are highly vari-
able, making clinical recognition and severity assessment
very challenging. Sepsis is a time-sensitive emergency, and
therefore early diagnostic markers are of paramount im-
portance to improve outcomes. Furthermore, prognostic
markers may help improve triage and patient manage-
ment. Table 1 summarises the diagnostic and prognostic
biomarkers review in this section.
Presepsin is a subtype of soluble CD14, which is a recep-
tor for LPS and LPS binding protein complexes expressed
on macrophage, monocyte, and granulocyte cells. Previous
clinical studies have found that plasma presepsin levels
were increased in sepsis and correlated with sepsis severity
[15]. Two different studies published in Critical Care have
evaluated this new potential diagnostic and prognostic
biomarker in patients admitted to the emergency depart-
ment with SIRS criteria. The diagnostic accuracy for sepsis
of presepsin found by Liu and colleagues was correct with
Table 1 Summary of diagnostic and prognostic performance of cited biomarkers
Biomarker Context Performance Reference
Diagnostic markers
PSP, sCD25, and HBP within 6 hours
of admission
Prospective monocentric; 219
patients admitted to the ICU
Diagnosis of sepsis versus SIRS: PSP
(cutoff value 30 ng/ml), Se 90% and
Sp 83%; sCD25 (cutoff value 2.5 ng/ml),
Se 83% and Sp 83%; HBP (cutoff value
50 ng/ml), Se 78% and Sp 36%
[20]
sCD25, IL-10, and IFNγ on days 1 and
7 of hospital admission
Prospective monocentric; 52
patients with SIRS criteria
Diagnosis of bacteriaemic SIRS (day 1):
sCD25 (cutoff value 19.9 ng/ml), Se 83%
and Sp 83%; IL-10 (cutoff value 3.05 pg/ml),
Se 88% and Sp 75%; IFNγ (cutoff value
9 pg/ml), Se 45% and Sp 70%
[21]
Presepsin at admission Prospective monocentric; 859
ED patients with SIRS criteria
Presepsin >317 pg/ml: diagnosis of sepsis,
Se 71% and Sp 86%
[16]
Presepsin at admission Prospective bicentric; 186 ED
patients with SIRS criteria
Presepsin >600 pg/ml: diagnosis of sepsis,
Se 79% and Sp 62%
[17]
Prognostic markers
Red blood cell distribution width at
admission and at 72 hours
Prospective monocentric; 329
ED patients, severe sepsis or
septic shock
Increased baseline RDW and ΔRDW at
72 hours after admission >0.2%: 28-day
mortality, OR =9.97 (95% CI =1.99 to 49.91);
hospital length of stay, OR =25.45
(95% CI =14.69 to 36.21
[30]
PCT change at 72 hours from baseline Retrospective multicentre; 154
ED patients with sepsis
Per 10% PCT increase from baseline: ICU
mortality, OR =1.3 (95% CI =1.1 to 1.15); 80%
PCT decrease from baseline: ICU mortality,
Se 91% and NPV 90%
[22]
sCD25 and IL-10 at days 1 and 7
of hospital admission
Prospective monocentric; 52
patients admitted to the
hospital with SIRS
ICU mortality of bacteriaemic patients with
SIRS: day 1 sCD25 > 19.9 ng/ml, OR =1.12
(95% CI =1.01 to 1.25); day 1 IL-10 > 3.05
pg/ml, OR =1.86 (95% CI =0.98 to 3.52)
[21]
Presepsin at admission Prospective monocentric; 859
ED patients with SIRS criteria
Evolution to severe sepsis (cutoff value
449 pg/ml), Se 82% and Sp 72%; evolution
to septic shock (cutoff value 550 pg/ml), Se
86% and Sp 64%; 28-day mortality (cutoff
value 556 pg/ml), Se 62% and Sp 67%
[16]
Serum MDA at day 1 Prospective multicentre; 328
patients with severe sepsis
MDA >4.11 nmol/l: 30-day mortality, HR =1.05
(95% CI =1.02 to 1.09); 6-month mortality,
HR =1.05 (95% CI =1.02 to 1.09)
[36]
372 T/C polymorphism of TIMP-1 Prospective multicentre; 275
patients with severe sepsis
If 372 T/C polymorphism present: 30-day
mortality, OR =2.08 (95% CI =1.06 to 4.09)
[37]
Kallistatin at days 1 and 4 Prospective monocentric; 54
ICU patients with severe CAP
Kallistatin >8.3 μg/ml: ICU mortality, OR =0.11
(95% CI =0.01 to 1.06)
[18]
Ang-1/Ang-2 ratio at fever onset Prospective bicentric; 99 cancer
and chemotherapy-induced
febrile neutropaenia patients
Ang-1/Ang-2 ratio >5: development of septic
shock, RR =5.47 (95% CI =1.93 to 15.53);
28-day mortality, RR =4.20 (95% CI =1.60
to 11.05)
[28]
Ang, angiopoietin; CAP, community-acquired pneumonia; CI, confidence interval; ED, emergency department; HBP, heparin binding protein; HR, hazard ratio; IFNγ,
interferon gamma; IL, interleukin; MDA, malondialdehyde; NPV, negative predictive value; OR, odds ratio; PCT, procalcitonin; PSP, pancreatic stone protein; RDW,
red blood cell distribution width; RR, relative risk; sCD25, soluble CD25; Se, sensitivity; SIRS, systemic inflammatory response syndrome; Sp, specificity; TIMP-1,
tissue inhibitor of matrix metalloproteinase 1.
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value of 317 pg/ml. Presepsin was found to be an inde-
pendent predictor of severe sepsis and septic shock com-
pared with septic patients, and was an independent
predictor of 28-day mortality [16]. In the second study by
Ulla and colleagues, the sensitivity and specificity of pre-
sepsin for a cutoff value of 600 pg/ml were, respectively,
79% and 62%. Presepsin values at admission to theemergency department correlated with 60-day in-hospital
mortality in patients with severe sepsis and septic shock
[17]. These studies indicate that presepsin could be a
promising tool for diagnosing sepsis in the emergency de-
partment, and appears superior to procalcitonin (PCT) for
risk stratification and evaluation of prognosis.
Lin and colleagues evaluated kallistatin levels in pa-
tients with severe community-acquired pneumonia [18].
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who had septic shock and developed ARDS, and the sen-
sitivity and specificity for predicting death for a cutoff
value of 6.5 μg/ml were, respectively, 81% and 54%.
These findings indicate that kallistatin may be protective
against severe community-acquired pneumonia, which
implies possible therapeutic benefits of kallistatin in
these patients. Indeed, in a recent experimental study of
a mouse polymicrobial sepsis model, administration of
kallistatin reduced systemic inflammation and endothe-
lial activation, and improved survival [19].
In 219 unselected patients admitted to an ICU, three
diagnostic biomarkers were evaluated and compared
with PCT: pancreatic stone protein, a lectin-binding pro-
tein; soluble CD25 (sCD25), which is the soluble form of
the IL-2 receptor alpha chain; and heparin binding pro-
tein, an inflammatory mediator contained in neutrophil
secretory granules [20]. All biomarkers were measured
in plasma collected within 6 hours of admission. Levels
of PCT, pancreatic stone protein, and sCD25, but not of
heparin binding protein, were significantly higher in sep-
tic patients than in noninfectious SIRS patients. Using
receiver operating characteristic analysis, the optimal
cutoff values were 30 ng/ml (sensitivity 90%, specificity
83%) for pancreatic stone protein and 2.5 ng/ml (sensi-
tivity 83%, specificity 83%) for sCD25. In comparison,
PCT with a cutoff value of 1 ng/ml had a sensitivity of
71% and specificity of 82%. In this study, pancreatic
stone protein and sCD25 performed at least as well as
PCT for sepsis diagnosis in SIRS patients, and warrant
further assessment for clinical decision making.
In a prospective study of 52 patients admitted with
SIRS, diagnostic performance for bacteraemia at day 1 of
IL-10 and sCD25 showed respectively sensitivity/specifi-
city of 78%/80% and 87%/75% [21]. In multivariate ana-
lysis, IL-10 and sCD25 at day 1 were independent
predictors of mortality (respectively odds ratio (OR)
=1.86 and OR =1.12, P <0.05). In conclusion, sCD25 and
IL-10 are early diagnostic and prognostic markers but
lack sensitivity and cannot be recommended for routine
use at the moment.
In a US-based retrospective observational multicentre
study, the prognostic information obtainable from a
change of PCT at 72 hours from baseline value was in-
vestigated in a cohort of 154 patients admitted to the
ICU with a diagnosis of sepsis [22]. A PCT increase be-
tween baseline and 72 hours after ICU admission was
associated with increased ICU mortality (OR per 10%
PCT increase =1.3, 95% confidence interval (CI) =1.1 to
1.5, P =0.001). With a cutoff value of 80% PCT decrease
at 72 hours, the sensitivity and the negative predictive
value for ICU mortality were excellent, respectively 91%
and 90%. These data suggest that a PCT decrease >80%
at 72 hours after ICU admission may help to identifypatients with reduced mortality risk, and prompt early
ICU discharge.
Downregulation of monocyte human leukocyte antigen
DR (HLA-DR) surface expression measured by flow cy-
tometry has been identified as a biomarker of sepsis-
induced immunosuppression [23]. Flow cytometry can
be difficult to perform due to specific laboratory require-
ments. Cajander and colleagues demonstrated that the
mRNA expression level of HLA-DR monitored by quan-
titative real-time polymerase chain reaction correlates
highly with surface expression of HLA-DR measured by
flow cytometry and could become a routine technique in
this context [24]. Immunoparalysis is also characterised
by defective B lymphocytes and low immunoglobulin
production, including immunoglobulin M (IgM) that is
crucial for the opsonisation and clearance of invading
microorganisms. Giamarellos-Bourboulis and colleagues
demonstrated in 332 critically ill patients with SIRS that
IgM levels in patients with severe sepsis progressing to
septic shock remained stable in nonsurvivors, whereas
IgM of survivors presented an early peak with a subse-
quent gradual decrease [25]. However, there are to date
insufficient data to use IgM level kinetics as prognostic
markers. Of note, the use of IgM-enriched immuno-
globulin preparation in a recent trial of 33 septic shock
patients failed to improve mortality as compared with
standard therapy [26].
Angiopoietin (Ang)-1 and Ang-2 play a critical role for
endothelial barrier integrity. The Ang-2/Ang-1 ratio has
emerged as a promising endothelial-associated sepsis
biomarker [27]. In a prospective study of 99 patients
with cancer and chemotherapy-induced febrile neutro-
paenia, Luz Fiusa and colleagues evaluated the serum
Ang-2/Ang-1 ratio at fever onset as a prognostic bio-
marker [28]. The Ang-2/Ang-1 ratio was much higher in
patients who developed septic shock compared with pa-
tients with noncomplicated febrile neutropaenia. For an
Ang-2/Ang-1 ratio >5, the relative risk of developing
septic shock was 5.47 (95% CI =1.93 to 15.53, P =0.001).
The 28-day mortality risk for a ratio >5 was 4.20 (95%
CI =1.60 to 11.05, P =0.004), confirming that the Ang-2/
Ang-1 ratio is a biomarker of septic shock development
and poor outcome for febrile neutropaenia patients. As
the severity of microvascular alterations is strongly asso-
ciated with organ dysfunction and mortality [29], the
Ang-2/Ang-1 ratio appears to be of particular interest.
At this stage, however, therapies to specifically target the
microcirculation are still being investigated.
The red blood cell distribution width represents an
index of the heterogeneity of erythrocytes and has been
shown to have predictive value for all-cause mortality in
critically ill patients, although the mechanism of the as-
sociation remains unclear. Kim and colleagues demon-
strated in 329 severe sepsis and septic shock patients
de Montmollin and Annane Critical Care 2014, 18:578 Page 5 of 8
http://ccforum.com/content/18/5/578that the combination of both an increased red blood
cell distribution width at baseline and an increase in
red blood cell distribution width from baseline during
the first 72 hours after admission was an independent
predictor of 28-day mortality (OR =9.97, 95% CI =1.99
to 49.91, P =0.005) [30]. These results are in accord-
ance with those of Sadaka and colleagues, who showed
that the red blood cell distribution width at day 1 in
septic shock patients fared better than either the Acute
Physiology and Chronic Health Evaluation II or Se-
quential Organ Failure Assessment score as a prognos-
tic marker [31].
The Japanese Association for Acute Medicine Dissemi-
nated Intravascular Coagulation scoring system includes
SIRS criteria, platelet count, fibrinogen level, and pro-
thrombin time [32]. Gando and colleagues showed that
disseminated intravascular coagulation-positive patients
with severe sepsis at admission exhibited higher preva-
lence of septic shock and positive blood cultures [33]. The
28-day mortality gradually increased with the Japanese As-
sociation for Acute Medicine Disseminated Intravascular
Coagulation score, and the score at day 1 was an inde-
pendent predictor of 28-day mortality.
Abnormal body temperature is a frequent finding in pa-
tients with sepsis, and it was hypothesised that temperature
patterns could be early indicators of sepsis and prognostic
markers. In a retrospective case–control study, Drewry
and colleagues identified abnormal temperature patterns
72 hours prior to clinical suspicion of sepsis (described as
an ‘increase in amplitude, change in frequency or loss of
variability’) in afebrile ICU patients as predictive of subse-
quent diagnosis of sepsis (OR =4.43, 95% CI =1.31 to 15.00,
P =0.017) [34]. In a second prospective multicentre obser-
vational study of 624 patients admitted to the ICU with se-
vere sepsis, Kushimoto and colleagues demonstrated that
hypothermia during the first 24 hours of diagnosis, defined
as body temperature ≤36.5°C, was identified as an inde-
pendent predictor of 28-day mortality in patients with se-
vere sepsis (OR =1.95, 95% CI =1.25 to 3.04, P =0.003) [35].
Elevated body temperature, in contrast, was not associated
with an increased disease severity or risk of mortality.
These findings are of importance, as temperature is easily
recorded at the bedside and could bring useful diagnostic
and prognostic information. However, care should be taken
regarding how and when body temperature is recorded,
which should be standardised in future prospective studies.
In a prospective multicentre observational study of
328 patients diagnosed with severe sepsis, Lorente and
colleagues demonstrated that serum MDA levels at days
1, 4, and 8 were significantly higher in nonsurviving sep-
tic patients compared with survivors [36]. For a cutoff
value of 4.11 nmol/l, the sensitivity and specificity
to predict mortality were only respectively 42% and
82%. Overall, although high MDA levels are sustainedthroughout the first week of sepsis, the clinical utility for
predicting patient outcome is insufficient.
The 372 T/C polymorphism of tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1) is the most studied genetic
variant of this regulator of matrix metalloproteinases, in-
volved in leukocyte recruitment and modulation of inflam-
matory and prothrombotic response in sepsis [37]. Lorente
and colleagues showed that the 372 T/C genetic poly-
morphism of TIMP-1 was associated with higher serum
levels of TIMP-1 and higher 30-day mortality (OR =2.08,
95% CI =1.06 to 4.09, P =0.03) [38]. Determination of the
372 T/C genetic polymorphism of TIMP-1 has prognostic
implications and could help in the selection of patients




The immunosuppressive state of late sepsis makes patients
more at risk of secondary nosocomial infections, amongst
them fungal infections. Programmed cell death-1 and cyto-
toxic T-lymphocyte antigen 4 are negative co-stimulatory
molecules that suppress T-cell function. In an experimental
study of a mouse model of primary candidaemia and a
two-hit model of caecal ligation and puncture followed
by candidaemia, antibody blockade of either programmed
cell death-1, programmed cell death-1 ligand, or cytotoxic
T-lymphocyte antigen 4 significantly improved survival
[39]. This survival improvement was associated with in-
creased production of interferon gamma and reversion of
the fungal-induced depression of HLA-DR expression on
monocytes and dendritic cells. Furthermore, in an in vitro
study on blood from septic critically ill patients, blockade
of the programmed cell death-1–programmed cell death-1
ligand pathway decreased apoptosis and improved immune
cell function [40]. These data support the concept that
immune-adjuvant therapy could improve the treatment of
fungal infections.
Glycyrrhizin is a glycoside compound extracted from the
plant Glycyrrhiza glabra, and has shown anti-inflammatory
properties via binding to HMGB-1 and inhibition of this
late sepsis proinflammatory cytokine [41]. Wang and col-
leagues demonstrated in a porcine endotoxaemic model
that glycyrrhizin improved systemic haemodynamics and
enhanced pulmonary oxygen exchange [42]. Serum proin-
flammatory cytokine levels were reduced, and infiltration
by inflammatory cells was significantly reduced in the lung,
liver, and kidney tissues. Thus, through modulation of the
inflammatory response and attenuation of organ damage,
glycyrrhizin should be seen as a potential agent in the
treatment of sepsis and requires additional experimental
and clinical investigation.
Antimicrobial peptides are proteins able to bind and
neutralise LPS, and may kill bacteria without releasing
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of the mouse caecal ligation and puncture septic model,
effects of a newly synthetised antimicrobial peptide,
coined Pep 2.5, were assessed [44]. The authors demon-
strated that continuous infusion of Pep 2.5 reduced cir-
culating proinflammatory mediator levels (IL-6, IL-10,
and MCP-1) compared with the sepsis control group,
and that Pep 2.5 reduced CD14 (contributor to the
TLR4-mediated LPS recognition) mRNA tissue expres-
sion in the heart, lung, and spleen compared with con-
trols. This antimicrobial peptide may thus have the
potential for further development as an anti-infective
treatment in sepsis.
Human studies
Rimmelé and colleagues showed that the use of haemoad-
sorption devices on the blood of septic shock patients
enabled the capture of monocytes and neutrophils, but
not lymphocytes, and led to a local release of IL-8 and
changes in T-cell function [45]. This more systematic
approach with tight immune monitoring is important to
better understand the action of haemoadsorption de-
vices in sepsis.
Thymosin alpha 1 (Tα1) is a thymic peptide that has
immunomodulating effects primarily by affecting the
enhancement of T-cell functions [46]. In a multicentre
randomised control trial including 361 patients with se-
vere sepsis admitted to the ICU, Wu and colleagues
showed that administration of Tα1 for 5 days after sep-
sis diagnosis significantly reduced in-hospital mortality
compared with placebo (relative risk of death 0.73, 95%
CI =0.54 to 0.98, P =0.032), but with no significant dif-
ference in ICU mortality, length of ICU stay, and dur-
ation of mechanical ventilation [47]. Of note, greater
improvement in mHLA-DR was observed in the Tα1
group at days 3 and 5, suggesting improved immune
function in this group compared with placebo. This
study, the first and only one conducted in patients with
severe sepsis, demonstrates that Tα1 therapy could re-
duce mortality, and that larger multicentre trials are
warranted to confirm these findings.
Analysing human studies of potential new therapies in
sepsis, it is important to acknowledge that the overall mor-
tality associated with septic shock has now decreased to
18% in the most recent trials [48,49]. This improvement
results from the implementation of international guide-
lines [1] and generalisation of interventions such as early
administration of appropriate antibiotics, fluid resuscita-
tion, and so forth. The challenge to demonstrate a mortal-
ity benefit with new therapies will now be greater given
the lower baseline mortality. In this respect, the study by
Wu and colleagues demonstrating a reduction in hospital
mortality after administration of the immunomodulating
agent Tα1 is of particular interest.Outcome studies
Many patients surviving sepsis will develop complica-
tions associated with significant long-term sequelae that
will impact on health-related quality of life. Previous
follow-up studies of sepsis patients with evaluation of
quality of life did not exceed 3 years, and thus Cuthbertson
and colleagues conducted a prospective cohort study on
439 patients with severe sepsis with a quality of life
follow-up (with Short Form-36 and euroQOL-5D ques-
tionnaires) at 3.5 and 5 years [50]. Patients had an on-
going high mortality after severe sepsis with survival
rates of 57% in hospital, 42% at 3.5 years, and 39% at
5 years. Furthermore, patients had significantly lower
physical quality of life compared with the population
norm, but only slightly reduced mental quality-of-life
scores. These data, similar to other critically ill cohorts,
give invaluable insights for the improvement of long-
term post-ICU care [51] and when evaluating cost-
effectiveness of care in severe sepsis patients.
In a prospective observational study of 1,001 patients
admitted to the ICU for severe sepsis between 2004 and
2009, Phua and colleagues showed that 41.5% of patients
had negative culture [52]. Culture-negative patients had
fewer comorbid conditions and lower Acute Physiology
and Chronic Health Evaluation II and Sequential Organ
Failure Assessment scores, and the lungs were the most
frequent site of infection. While providing useful data on
culture-negative sepsis, this study cannot conclude on
the very nature of culture-negative sepsis, and further
studies are warranted on this topic.
Sakr and colleagues investigated the influence of gen-
der on the epidemiology of severe sepsis in ICU patients,
and its possible impact on mortality [53], and showed
that prevalence of severe sepsis was lower in female pa-
tients but female gender was independently associated
with a higher risk of in-ICU death in patients with se-
vere sepsis (OR =2.33, 95% CI =1.23 to 4.39, P =0.009).
These epidemiological findings should lead to further in-
vestigations of the relation between immune response to
sepsis and sex steroid hormones.
Conclusion
This year in review has reviewed articles published in Crit-
ical Care and other relevant journals in 2013. Much work
has been done to better understand the pathophysiology
of sepsis, and advances have been made concerning the
immune and inflammatory response, oxidative stress, and
mitochondrial dysfunction. Several studies concerned the
evaluation of diagnostic and prognostic biomarkers. Some
of these biomarkers seem promising, and future research
in the sepsis field should emphasise these markers because
early recognition of severe sepsis or septic shock is para-
mount to improve patient survival. In this respect, new
rapid identification of causative pathogens by techniques
de Montmollin and Annane Critical Care 2014, 18:578 Page 7 of 8
http://ccforum.com/content/18/5/578such as mass spectrometry and real-time polymerase
chain reaction is also a major evolution for patient care.
The observed reduction in mortality from patients with
sepsis in the past decade has come mainly from the im-
provement of supportive care. Further improvement in
outcome will come from identification of new therapeutic
targets via basic and clinical research.Note: This article is part of a collection of Year in review articles
in Critical Care. Other articles in this series can be found at
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